Achillion Pharmaceuticals, Inc.
) recently commenced international phase II studies on sovaprevir
and ACH-3102 for the treatment of genotype 1 chronic hepatitis C
(HCV). The trial will assess an all-oral 12-week interferon-free
regimen consisting of sovaprevir, ACH-3102, and ribavirin in 50
treatment-naïve patients with chronic HCV.
Safety, tolerability, and sustained virologic response four
weeks after the completion of dosing (SVR4) are the primary
endpoints of the trial.
ACH-3102 is being evaluated in various combinations. Earlier,
Achillion reported interim phase II results from a study
consisting of ACH-3102 and ribavirin for the treatment of
genotype 1b, IL28B CC genotype, HCV. The results indicated that 6
out of 8 patients who received 12 weeks of therapy achieved rapid
virologic response (RVR).
According to information provided by Achillion, more than 170
million people are infected with HCV across the world. HCV
affects more than 5 million people in the US which is more than
twice as prevalent as HIV.
Achillion has three lead candidates for the treatment of HCV,
namely, sovaprevir and ACH-3102 (both in phase II), and ACH-2684
Sovaprevir and ACH-2684 are NS3 protease inhibitors while
ACH-3102 is an NS5A inhibitor. The HCV market is currently has
products like Victrelis, Incivek, Pegasys, Roferon-A, Intron-A
and Peg-Intron. Currently many large cap companies are also
developing drugs for the treatment of HCV.
Achillion carries a Zacks Rank #3 (Hold). Currently companies
Vertex Pharmaceuticals Incorporated
Cleveland BioLabs, Inc.
Transcept Pharmaceuticals, Inc.
) look more attractive with a ZacksRank #1 (Strong Buy).
ACHILLION PHARM (ACHN): Free Stock Analysis
CLEVELAND BIOLB (CBLI): Free Stock Analysis
TRANSCEPT PHARM (TSPT): Get Free Report
VERTEX PHARM (VRTX): Free Stock Analysis
To read this article on Zacks.com click here.